NA
ONCT

NewEdge Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

NewEdge Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1
Closed -$1.08K – 1187
2017
Q2 		$1.08K Buy
+1
New +$613 ﹤0.01% 1347

Other funds holding ONCT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FHA
First Horizon Advisors Memphis, Tennessee $3.85B AUM 16.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

NewEdge Advisors's ONCT Position: Q3 2017 in Review

NewEdge Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2017, closing a stake of 1 share — an estimated $1.08K sold.

NewEdge Advisors first reported a position in ONCT in Q2 2017 and held it in 1 quarter. The position peaked at $1.08K in Q2 2017. 20 funds tracked by Wall St. Rank hold ONCT as of Q3 2017.

  • NewEdge Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • NewEdge Advisors sold 1 Oncternal Therapeutics, Inc. Common Stock share in Q3 2017, an estimated $1.08K.
  • NewEdge Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • NewEdge Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $1.08K in Q2 2017.
  • 20 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2017.

Based on NewEdge Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.